C-RAD enters Croatian market by receiving largest order in Central Eastern Europe to date, supplying numerous state-of-the-art SGRT systems through a public tender, with an order value of 16 MSEK. The order was signed and recognized as order intake in the fourth quarter of 2023.

C-RAD announces entering a new European market and a significant milestone in advancing radiotherapy in Central Eastern Europe, with an order for multiple Catalyst+ HD to be installed in Croatian radiotherapy centers. C-RAD’s products were included in Elekta’s submission to the public tender for linear accelerators, organized by the Croatian Ministry of Health under the funding of European Union, awarded at the end of 2023. Total order value from Elekta Solutions AB (main supplier) amounts to 16 MSEK.

The supply includes multiple linear accelerators, each bearing a Catalyst+ HD SGRT system for positioning, motion monitoring and Deep Inspiration Breath Hold treatments. Catalyst+ HD system supports the entire radiotherapy workflow, ensuring optimal treatment outcomes without exposing patients to non-prescribed radiation doses. The systems will be supplied to 3 (three) Radiation Therapy departments in the cities of Zagreb (KBC Sestre Milosrdnice hospital), Osijek (KBC Osijek hospital) and Split (KBC Split hospital), representing a prominent entrance into the Croatian market for C-RAD.

Cecilia de Leeuw, CEO and president of C-RAD, comments: “This is a significant step towards establishing SGRT as the standard of care in Central Eastern Europe and I especially congratulate the Ministry of Health for investing into advanced radiation oncology equipment by mandating each linear accelerator with SGRT technology, that supports DIBH technique. We are truly enthusiastic about entering this new market together with our partner Elekta and honored about the designation of C-RAD Catalyst+ HD systems for multiple centers across Croatia”.

The deliveries are expected to start in the second half of 2024 and will continue over several quarters.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com
Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

Attachments

C-RAD wins order in Croatia of 16 MSEK

© Modular Finance, source Nordic Press Releases